NCT06004401View on ClinicalTrials.gov

The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori

NANot yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
The Eradication Rate of Helicobacter Pylori
Interventions
DRUG

Vonopazan +Amoxicillin

Vonopazan 20mg 2//day+Amoxicillin

DRUG

Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin

Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day

DRUG

Vonopazan +Minocycline

Vonopazan 20mg 2/day+Minocycline 100mg 2/day

DRUG

Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin

Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER

NCT06004401 - The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori | Biotech Hunter | Biotech Hunter